Clinical trial register · Italy

Clinical Trials in Ancona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC

6778

Studies in scope

all four open statuses

4069

Recruiting now

open to new participants

1018

Lead sponsors

across recruiting studies

Top sites

Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967

Trials with a site in Ancona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Italy

Start

Not yet open

Evaluating Practices That Foster Care Partnerships and Wellbeing Among Informal Carers and Long-term Care Workers

NCT07708649Mental Wellbeing

VU University of Amsterdam

Not applicable

450

Ancona

2027-01-01

Not yet open

Biomarkers of Neurodegeneration, Synaptic Plasticity and Neuroinflammation in Dravet Syndrome

NCT07801404Dravet Syndrome (DS)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

Ancona, Florence, Genova, Messina, Milan, Roma, Rome, Verona

2026-09-15

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Bologna, Cona, Meldola, Rome, Milan, Ancona, Catania, Florence

2026-09-10

Not yet open

Vapor Ablation for Localized Cancer Lesions

NCT03514329Non Small Cell Lung Cancer, Metastatic Lung Cancer, Lung Cancer

Uptake Medical Technology, Inc.

Not applicable

Ancona

2026-09-01

Not yet open

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336Diabetes Mellitus, Type 2

DrugsDulaglutide·Orforglipron

Eli Lilly and Company

Phase 3

170

Ancona, Florence, Genova, Messina, Milan, Naples, Verona

2026-09

Not yet open

Neurocognitive Assessment in Long-Term Survivors of Lymphoma

NCT07652476Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B Cell Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

100

Ancona, Aviano, Bari, Legnano, Milan, Palermo

2026-09

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Ancona, Bergamo, Brescia, Milan, Pavia, Perugia, Riccione, Salerno

2026-08-24

Recruiting

Intracardiac Echocardiography-guided Versus Electroanatomical Mapping-guided Pulsed Field Ablation for Paroxysmal Atrial Fibrillation

NCT07772518Paroxysmal Atrial Fibrillation (PAF)

Mitera Hospital

Not applicable

292

Ancona

2026-08-01

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Ancona, Bari, Florence, Milan, Modena, Naples, Roma

2026-07-27

Recruiting

Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation

NCT07692490Liver Transplantation (LT), Ischemia-Reperfusion Injury, Early Allograft Dysfunction

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies

Not applicable

170

Ancona, Bari, Bergamo, Bologna, Genova, Modena, Padova, Palermo

2026-07-07

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Ancona, Bergamo, Bologna, Brescia, Cona, Florence, Pozzilli, Milan

2026-05-11

Not yet open

Standardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies

NCT07503366Type 1 Diabetes (T1D), Autoantibodies, Hyperglycemia, Impaired Glucose Tolerance (Prediabetes)

Società Italiana di Endocrinologia e Diabetologia Pediatrica

Observational

300

Ancona, Bari, Bolzano, Caserta, Catanzaro, Crotone, Florence, L’Aquila

2026-05

Not yet open

Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment

NCT07476105Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B

Fondazione Italiana Linfomi - ETS

Not applicable

170

Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan

2026-05

Not yet open

Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy

NCT07463781Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)

Fondazione Italiana Linfomi - ETS

Observational

100

Alessandria, Ancona, Brescia, Palermo, Reggio Calabria, Roma, Taranto, Udine

2026-05

Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670Diffuse Cutaneous Systemic Sclerosis

Mediar Therapeutics

Phase 2

Ancona, Catania, Genoa, Milan, Modena, Roma

2026-04-16

Recruiting

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

NCT07607769Hepatocellular Carcinoma

AstraZeneca

Observational

200

Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova

2026-04-16

Not yet open

Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?

NCT07295522Heart Failure, Acute Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)

DrugGDMT

IRCCS Policlinico S. Donato

Phase 4

368

San Donato Milanese, Ancona, Bari, Cecina, Ferrara, Florence, Milan, Pisa

2026-04-08

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Ancona, Bari, Bologna, Messina, Milan, Pavia, San Giovanni Rotondo (FG), Verona

2026-03-23

Recruiting

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

NCT07381764Metastatic Colorectal Cancer (CRC)

DrugsErbitux·Trifluridine/Tipiracil·Cetuximab·Irinotecan

Gruppo Oncologico Italia Meridionale

Phase 2

150

Alessandria, Ancona, Aviano, Caserta, Castellana Grotte, Catania, Catanzaro, Florence

2026-03-20

Recruiting

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

NCT07457580Type 1 Diabetes

DrugTeplizumab

Sanofi

Observational

Ancona, Palermo, Verona

2026-03-16

Recruiting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177Non-segmental Vitiligo

DrugGIA632

Novartis Pharmaceuticals

Phase 2

210

Ancona, Cona, Milan, Rozzano

2026-03-09

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Ancona, Aviano, Bari, Brescia, Candiolo, Catania, Milan, Naples

2026-03-05

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Ancona, Catania, Milan, Perugia, Roma, Rozzano, Torino, Udine

2026-03-05

Recruiting

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

NCT07595653Generalized Myasthenia Gravis (gMG), gMG

argenx

Observational

100

Acquaviva delle Fonti, Ancona, Bari, Bergamo, Bologna, Catanzaro, Florence, Genova

2026-02-25

Recruiting

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07222332Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

300

Ancona, Florence, Messina, Naples, Novara, Padova, Verona

2026-02-05

Not yet open

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

NCT07207785Mantle Cell Lymphoma

DrugPirtobrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Meldola, Rozzano, Ancona, Avellino, Biella, Bologna, Brescia, Catania

2026-02-01

Recruiting

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222137Diabetes Mellitus, Type 1

DrugBaricitinib

Eli Lilly and Company

Phase 3

150

Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova

2026-01-12

Recruiting

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

120

Rome, Ancona

2026-01-08

Recruiting

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

NCT07330245Lupus Erythematosus, Systemic

DrugAnifrolumab

AstraZeneca

Observational

218

Monserrato, Cona, San Giovanni Rotondo, Rozzano, Ancona, Bari, Brescia, Florence

2025-12-31

Recruiting

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562Multiple Myeloma

DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

1,000

Ancona, Cuneo, Florence, Genova, Legnano, Meldola, Milan, Reggio

2025-12-23

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Alessandria, Ancona, Bergamo, Bologna, Catania, Meldola, Livorno, Legnano

2025-12-22

Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

NCT07543419Hidradenitis Suppurativa

Novartis Pharmaceuticals

Observational

250

Ancona, Bari, Brescia, Cona, Florence, Genova, Lecce, Messina

2025-12-17

Recruiting

New Care Pathways for Supporting TRANSitional CARE From Hospital to Home Using AI and Personalized Digital Assistance

NCT07731126Transitional Care, Remote Patient Monitoring (RPM), Geriatric Multimorbidity

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

210

Ancona

2025-12-12

Not yet open

EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention

NCT07252388Acute Coronary Syndromes, Chronic Coronary Syndromes

Heart Care Foundation

Not applicable

240

Orbassano, Torino, Acquaviva delle Fonti, Ancona, Arzignano, Benevento, Cagliari, Caserta

2025-12-11

Recruiting

BaLloon-based PFA Ablation poST Approval Outcomes for PAF and PersAF

NCT07181590Paroxysmal AF, Atrial Arrhythmia, Atrial Fibrillation, Persistent Atrial Fibrillation

Abbott Medical Devices

Not applicable

300

Ancona, Milan

2025-12-11

Recruiting

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146Small-cell Lung Cancer

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 3

480

Ancona, Candiolo, Meldola, Ravenna, Roma, Verona

2025-11-30

Recruiting

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms

Eli Lilly and Company

Phase 2

204

Ancona, Modena, Pisa, Vicenza

2025-11-28

Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803Atopic Dermatitis

Sanofi

Observational

1,000

Ancona, Novara, Reggio Emilia, Roma

2025-11-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Ancona, Bergamo, Foggia, Pozzilli, Pavia, Roma, Gallarate, Naples

2025-11-11

Recruiting

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT07007065Neovascular Age-related Macular Degeneration

DrugSurabgene Lomparvovec

AbbVie

Phase 3

561

Cona, Florence, Rome, Ancona, Reggio Emilia

2025-11-05

Recruiting

Connected Care for Type 2 Diabetes Self-Management

NCT07149610Diabetes Type 2

Marche Region Regional Health Agency

Not applicable

388

Ancona, Fabriano, Iesi, Ascoli Piceno, San Benedetto del Tronto, Fermo, Civitanova Marche, Province of Macerata

2025-10-13

Recruiting

Reference Intervals With Indirect Methods in Italy

NCT07433777Reference Intervals

Centro di Riferimento Oncologico - Aviano

Observational

1,000,000

Altamura, Ancona, Arezzo, Belluno, Florence, Milan, Modena, Monza

2025-10-08

Recruiting

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913Mania, Bipolar Disorder

DrugKarXT

Bristol-Myers Squibb

Phase 3

424

Milan, Pisa, Siena, Ancona, Genova

2025-10-08

Recruiting

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma

DrugPonsegromab

Pfizer

Phase 2/3

982

Milan, Florence, Ancona, Foggia

2025-10-03

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Ancona, Avellino, Aviano, Bari, Brescia, Castellana Grotte, Catania, Catanzaro

2025-10-01

Not yet open

LUpus Eritematoso Sistemico NETwork and Registry

NCT07175610Systemic Lupus Erythematous (SLE)

Società Italiana di Allergologia, Asma e Immunologia Clinica

Observational

1,500

Ancona, Bari, Battipaglia, Cagliari, Florence, Mantua, Milan, Naples

2025-09-30

Recruiting

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

NCT06865417Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

Alessandria, Ancona, Milan, Naples, Rome, Trieste

2025-09-29

Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk

DrugZilebesiran

Alnylam Pharmaceuticals

Phase 3

11,000

Ancona, Cittadella, Lecco, L’Aquila, Messina, Milan, Naples, Novara

2025-09-22

Not yet open

Tele-Rehabilitation Intervention in Community-Based Healthcare for Patients With Parkinson's Disease (DHEAL-COM-PD)

NCT06984393Parkinson Disease, Older People

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

Ancona

2025-09-02

Not yet open

Tele-Rehabilitation Intervention in Community-Based Healthcare for Patients With Osteoporosis (DHEAL-COM-OP)

NCT06984380Osteoporosis, Older People

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

Ancona

2025-09-01

Not yet open

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

NCT07046663Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Fondazione Italiana Linfomi - ETS

Observational

190

Ancona, Bergamo, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-09

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Ancona, Brescia, Candiolo, Cona, Florence, Livorno, Meldola, Milan

2025-08-26

Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759Neovascular Age-Related Macular Degeneration (nAMD)

DrugsEYLEA (aflibercept)·4D-150 IVT

4D Molecular Therapeutics

Phase 3

480

Ancona

2025-07-22

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Milan, Pisa, Siena, Ancona, Genova

2025-07-18

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

Ancona, Bari, Meldola, Milan, Monza, Pisa, Ravenna, Roma

2025-07-17

Recruiting

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

NCT06898515Acute Decompensated Heart Failure

DrugFurosemide

Reprieve Cardiovascular, Inc

Phase 3

400

Ancona, Bergamo, Milan

2025-07-14

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Ancona, Bologna, Brescia, Florence, Forlì, Lecce, Milan, Naples

2025-07-02

Recruiting

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

NCT06486883Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma

DrugsCDK4/6i·Trastuzumab deruxtecan

MedSIR

Phase 2

200

Ancona, Aviano, Florence, Genova, Milan, Modena, Monza, Naples

2025-06-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

2,400

Monza, Livorno, Ancona, Bergamo, Genova, Milan, Pisa, Reggio Emilia

2025-06-30

Recruiting

Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy

NCT06994377Metastatic Breast Cancer

European Institute of Oncology

Observational

1,000

Ancona, Aviano, Bagno a Ripoli, Bari, Bergamo, Brescia, Brindisi, Busto Arsizio

2025-06-25

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Milan, Pisa, Siena, Ancona, Genova

2025-06-13

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Ancona, Bologna, Catania, Genova, Messina, Milan, Monza (MB), Naples

2025-06-09

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Ancona, Milan, Roma

2025-06-09

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Alessandria, Ancona, Bergamo, Bologna, Brescia, Catania, Florence, Genova

2025-06-04

Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

NCT06965374Parkinson Disease

AbbVie

Observational

270

Troina, Pozzilli, Milan, Naples, Turin, Rome, Venice, Ancona

2025-06-04

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Ancona, Cona, Pisa

2025-05-16

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Ancona, Turin, Florence, Milan, Pavia, Reggio Calabria, Rome, Rozzano

2025-05-06

Recruiting

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

NCT06588205Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Fondazione Italiana Linfomi - ETS

Observational

200

Alessandria, Ancona, Bari, Brescia, Candiolo, Castelfranco Veneto, Catania, Civitanova Marche

2025-05-05

Recruiting

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

NCT06652438Acute Myeloid Leukemia, Adult

DrugRevumenib

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3

448

Ancona, Bologna, Civitanova Marche, Milan, Pagani, Palermo, Perugia, Pescara

2025-05-05

Active, closed

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)

DrugsPelacarsen·Inclisiran

Novartis Pharmaceuticals

Phase 3

246

Ancona, Caserta, Grosseto, Milan, Rozzano, Perugia, Pordenone, Salerno

2025-04-30

Recruiting

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

NCT06835530Diffuse Large B Cell Non-Hodgkin Lymphoma

DrugsGolcadomide·Rituximab

Fondazione Italiana Linfomi - ETS

Phase 2

Alessandria, Pescara, Ancona, Avellino, Aviano, Brescia, Florence, Milan

2025-04-09

Recruiting

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)

NCT07435467Alzheimer Disease, Old Age; Dementia

Istituto Nazionale di Ricovero e Cura per Anziani

Observational

400

Ancona, Fermo, Messina

2025-04-09

Recruiting

A Socio-Technological Intervention in Community-Based Healthcare for Individuals With Mild Cognitive Impairment (DHEAL-COM-MCI)

NCT06984367Mild Cognitive Impairment, Older People

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

Ancona

2025-04-08

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Roma, Milan, Catania, Ancona

2025-04-01

Recruiting

Statin Effect on Arrhythmogenic Cardiomyopathy Disease Progression (SEARCH)

NCT06922994Arrhythmogenic Cardiomyopathy

DrugAtorvastatin

Centro Cardiologico Monzino

Phase 2

102

Pavia, Ancona, Milan, Naples

2025-03-31

Active, closed

E-Health Literacy Intervention for Bangladeshi Migrants With Type 2 Diabetes in Italy

NCT07783893Type 2 Diabetes, Diabete Mellitus

Marche Region Regional Health Agency

Observational

Ancona

2025-03-10

Recruiting

Inari VISION Registry

NCT06600542Pulmonary Embolism

Inari Medical

Observational

1,000

Ancona

2025-03-07

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Meldola, Milan, Rome, Orbassano, Ancona, Bologna

2025-03-06

Active, closed

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483Breast Cancer

DrugZelenectide pevedotin

BicycleTx Limited

Phase 2

Meldola, Ancona, Milan

2025-03-03

Recruiting

Assessment of Venous Return During Volume Expansion: a Prospective Observational Study

NCT07499388Hemodynamic Changes

Università Politecnica delle Marche

Observational

Ancona

2025-03-01

Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

Fondazione Italiana Linfomi - ETS

Observational

400

Ancona, Bari, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-02-27

Active, closed

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT06686615Primary Hypercholesterolemiia, Mixed Dyslipidemia

DrugsBempedoic acid·Ezetimibe·Rosuvastatin·Atorvastatin

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

2,000

Acquaviva delle Fonti, Ancona, Avellino, Bari, Bolzano, Brescia, Casale Monferrato, Caserta

2025-02-12

Recruiting

Advancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants

NCT06823466Ischemic Stroke, Oral Anticoagulation, Atrial Fibrillation (AF), Outcome Assessment

University of L'Aquila

Observational

200

Ancona, Bari, Bologna, Città di Castello, Ferrara, Florence, Frosinone, L’Aquila

2025-02-12

Recruiting

LEOPARD Training and Validation Data Collection Study

NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma

Assistance Publique - Hôpitaux de Paris

Observational

4,500

Ancona, Bari, Bologna, Genova, Milan, Modena, Naples, Padova

2025-02-04

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Rozzano, Milan, Naples, Rome, Ancona, Brescia, Campobasso, Catania

2025-01-31

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa

2025-01-31

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Rome, Ancona, Milan, Naples, Padova, Pisa, Reggio Emilia, Roma

2025-01-29

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Monza, Rionero in Vulture, Palermo, Candiolo, Ancona, Brescia, Milan, Novara

2025-01-27

Recruiting

Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT)

NCT06832644Cardiovascular Risk, Genetic Cardiovascular Risk

IRCCS Policlinico S. Donato

Not applicable

30,000

Milan, Ancona, Genova, Naples, Palermo, Pavia, Pozzilli, Rome

2025-01-22

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Alessandria, Ancona, Bari, Brescia, Catania, Genova, Milan, Naples

2025-01-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Ancona, Brescia, Catania, Milan, Naples, Pavia, Roma, Rozzano

2025-01-09

Recruiting

Hospitality Oriented Service Perception Evolution With Robots (HOSPER)

NCT07002411Quality of Hospital Entrance Reception, Social Robots

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

200

Ancona

2024-12-18

Active, closed

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06665256Idiopathic Inflammatory Myopathies

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

Ancona, Brescia, Monza, Milan, Rozzano, Verona

2024-12-17

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Ancona, Catania, Meldola FC, Palermo, Pavia, Pisa, Roma

2024-12-16

Recruiting

Evaluation of the Microcirculatory Response to Fluids in Critically Ill Patients With Venous Congestion: A Prospective Observational Study

NCT07499401Venous Congestion, Microcirculation, Volume Expansion

DrugFluid challenge

Università Politecnica delle Marche

Observational

Ancona

2024-12-15

Active, closed

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214Waldenström's Macroglobulinemia (WM)

DrugZanubrutinib

Fondazione Italiana Linfomi - ETS

Observational

212

Alessandria, Ancona, Ascoli Piceno, Bari, Biella, Bologna, Bolzano, Ferrara

2024-12-13

Active, closed

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

NCT06588686Idiopathic Pulmonary Fibrosis (IPF)

Vicore Pharma AB

Phase 2

378

Ancona, Bergamo, Monza, Roma, Turin

2024-12-09

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Ancona, Florence, Genova, Parma, Pavia, Roma, Bologna, Catania

2024-12-05

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Ancona, Bologna, Florence, Milan, Pavia, Roma, Torino

2024-12-03

Active, closed

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

NCT06543914Migraine

AbbVie

Observational

1,314

Milan, Naples, Turin, Rome, Ancona, Bari, Catanzaro, Pavia

2024-11-26

Recruiting

JACARDI: A eHealth and Health Literacy Educational Training to Support Older Patients With Type II Diabetes

NCT06904690Type 2 Diabetes

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

200

Ancona

2024-11-15

By invitation

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

NCT06472362Systemic Sclerosis

Royal Brompton & Harefield NHS Foundation Trust

Observational

1,000

Ancona, Sassari, Siena

2024-11-01

Recruiting

HRQoL and Financial Toxicity in Patients With VEXAS Syndrome

NCT06657846VEXAS

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

100

Ancona, Bergamo, Bologna, Brescia, Candiolo, Florence, Milan, Naples

2024-11-01

Recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

975

Rome, Milan, Florence, Ancona

2024-10-30

Active, closed

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896Scleroderma, Diffuse

DrugsRapcabtagene autoleucel·Rituximab

Novartis Pharmaceuticals

Phase 2

Ancona, Bergamo, Brescia, Genova, Milan, Pescara, Perugia, Pisa

2024-10-29

Active, closed

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837Follicular Lymphoma

DrugsMosunetuzumab·Zanubrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Candiolo, Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Milan

2024-10-23

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Ancona, Aviano (PN), Meldola (FC), Milan, Naples, Rome

2024-10-11

Recruiting

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

200

Ancona, Milan, Rozzano, Modena, Palermo, Pavia, Roma, Verona

2024-10-09

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Ancona, Brescia, Cagliari, Meldola, Milan, Naples, Rome, Rozzano

2024-09-25

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Ancona, Milan, Modena, Naples, Padova, Palermo, Pavia, Pisa

2024-09-11

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Ancona, Bari, Candiolo, Florence, Milan, Reggio Calabria

2024-09-10

Active, closed

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis

DrugRapcabtagene autoleucel

Novartis Pharmaceuticals

Phase 2

179

Alessandria, Ancona, Genova, Milan, Rozzano, Pescara, Pisa, Pavia

2024-09-04

Active, closed

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

NCT06345157Multiple Sclerosis, Relapsing-Remitting

DrugOfatumumab

Novartis Pharmaceuticals

Observational

379

Ancona, L’Aquila, Bari, Bergamo, Chieti, Catania, Catanzaro, Cona

2024-07-30

Recruiting

PulseSelect™ PFA Global Registry

NCT06393920Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

1,950

Negrar, Ancona

2024-07-23

Recruiting

TRAns-Femoral Access Intravascular Lithotripsy Comparison With PTA in TAVI

NCT05873842Trans-femoral TAVI With Calcified Ilio-femoral Arteries

Rede Optimus Hospitalar SA

Observational

Ancona, Mestre, Treviso, Verona, Vicenza

2024-07-22

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Ancona, Mantua, Milan, Naples, Torino, Verona

2024-07-11

Recruiting

GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting

NCT07583485Breast Cancer

Fondazione Oncotech

Observational

300

Avellino, Ancona, Aviano, Bari, Barletta, Bergamo, Caserta, Genova

2024-07-01

Recruiting

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6

Boehringer Ingelheim

Phase 1/2

768

Ancona, Candiolo (TO), Meldola (FC), Milan, Misterbianco (CT), Naples, Rozzano

2024-06-28

Recruiting

Underprescribing in Geriatric Patients: a Prevalence Study and Analysis of Factors Contributing to Potential Prescription Omissions (Under-PRES)

NCT06904638Older People

Istituto Nazionale di Ricovero e Cura per Anziani

Observational

374

Ancona, Cosenza

2024-06-20

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Ancona, Bari, Catania, Milan, Padova, Palermo, Pavia, Pisa

2024-06-20

Recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

NCT06311682Atopic Dermatitis

DrugTralokinumab

LEO Pharma

Phase 3

195

Ancona, Brescia, Padova, Roma, Rome

2024-06-10

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Ancona, Bergamo, Brescia, Meldola, Pisa, Rome

2024-06-07

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Forlì, Milan

2024-06-03

Recruiting

Italian PheNotypes Obstructive Sleep Apnea Study

NCT06872242Sleep Apnea

Istituto Auxologico Italiano

Observational

5,000

Acri, Ancona, Bari, Bergamo, Bologna, Cagliari, Catania, Corigliano-Rossano

2024-06-01

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Legnano, Turin, Rome, Ancona, Catania

2024-05-19

Recruiting

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates

Observational

2,000

Ancona, Bari, Pavia, Torino, Verona

2024-05-07

Recruiting

Silver Agri Age: Longevity, Intrinsic Capacity and Cognitive Impairment Into Farmlands and Natural Environments: Updating Contexts Following the "Montessori" Action

NCT06754202Mild Cognitive Impairment (MCI)

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

Ancona, Fermo

2024-05-03

Active, closed

Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

NCT06902857Type 2 Diabetes, Cardiovascular Complication

Istituto Nazionale di Ricovero e Cura per Anziani

Observational

964

Ancona

2024-04-18

Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

NCT06156774Non-hodgkin Lymphoma,B Cell

Fondazione Italiana Linfomi - ETS

Observational

130

Alessandria, Ancona, Avellino, Aviano, Brescia, Castelfranco Veneto, Florence, Milan

2024-04-18

Recruiting

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381Aortic Stenosis

DrugPelacarsen

Novartis Pharmaceuticals

Phase 2

502

Ancona, Bergamo, Bologna, Brescia, Caserta, Cona, Pozzilli, Milan

2024-03-07

Active, closed

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT05643638Graft Versus Host Disease, Acute

Cynata Therapeutics Limited

Phase 2

Ancona, Milan, Roma, Rozzano, San Giovanni Rotondo, Venezia

2024-03-04

Recruiting

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

NCT05934084Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Fondazione Italiana Linfomi - ETS

Not applicable

552

Ancona, Aviano, Bari, Belluno, Barletta, Bolzano, Brescia, Brindisi

2024-02-26

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Ancona, Florence, Genoa, Mestre, Milan, Naples, Pavia, Perugia

2024-02-21

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Meldola (Fc), Milan, Monza, Genova, Brescia, Roma, Ancona, Aviano (PN)

2024-02-21

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Milan, Legnano, Turin, Palermo, Ancona, Florence, Pisa, Bologna

2024-02-08

Recruiting

Geriatric Telemanagement of HEALTH Conditions in Nursing Home Residents Recently Discharged From the Hospital- GET HEALTH-I

NCT06893419Older Hospitalized Patients

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

102

Ancona

2024-02-04

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Ancona, Catania, Milan, Pisa, Roma, Rozzano

2024-01-30

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Bergamo, Catanzaro, Genova, Varese, Ancona, Brescia

2024-01-17

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Meldola, Ancona, Bologna, Brescia, Lecce, Ravenna, Roma, Rozzano

2024-01-05

Recruiting

Efficacy of a Myocardial Panel in the Management and Treatment of Pediatric Myocarditis

NCT07086144Myocarditis

Azienda Ospedaliero, Universitaria Ospedali Riuniti

Not applicable

Ancona

2024-01-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Cona, Meldola, Milan, Florence, Pisa, Castelfranco Veneto, Alessandria, Ancona

2023-12-31

Active, closed

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337Persistent Atrial Fibrillation

Boston Scientific Corporation

Not applicable

484

Ancona, Milan, Cotignola, Roma

2023-12-28

Recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

NCT06008691Non-Hodgkin Lymphoma, B-cell

DrugCombination

Fondazione Italiana Linfomi - ETS

Observational

1,500

Viagrande, Pescia, Alessandria, Ancona, Avellino, Aviano, Bari, Barletta

2023-12-27

Active, closed

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

NCT05948475Cholangiocarcinoma

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 3

200

Ancona, Candiolo, Meldola, Milan, Naples, Parma, Pisa, Rozzano

2023-12-20

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Ancona, Milan, Rozzano

2023-12-07

Recruiting

CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

NCT06158698Cardiomyopathies, Myocarditis, Inflammatory Cardiomyopathy, Heart Failure

DrugColchicine

Niguarda Hospital

Phase 3

Naples, Bologna, Trieste, Udine, Rome, Milan, Turin, Ancona

2023-11-14

Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

DrugsElironrasib·Cetuximab

Revolution Medicines, Inc.

Phase 1/2

534

Verona, Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna

2023-11-14

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

Ancona, Brescia, Cona, Milan, Padova, Roma

2023-11-08

Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

NCT06037980Biliary Tract Cancer, Cholangiocarcinoma

DrugsAbraxane·Nab-paclitaxel·Capecitabine·Gemcitabine

Gruppo Oncologico del Nord-Ovest

Phase 2/3

300

Ancona, Bergamo, Bologna, Brescia, Cuneo, Meldola, Milan, Modena

2023-11-07

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

NCT05696626Metastatic Breast Cancer

DrugsAbemaciclib·Fulvestrant

LeonaBio

Phase 3

600

Ancona, Aviano, Candiolo, Meldola, Milan, Misterbianco, Modena, Naples

2023-10-31

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Ancona, Milan, Salerno, Naples

2023-10-27

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Ancona, Aviano, Cremona, Genova, Lucca, Mantua, Milan, Monza

2023-10-26

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Ancona, Modena, Florence, Milan, Pisa, Roma, Trieste, Bergamo

2023-10-25

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

San Giovanni Rotondo, Meldola, Genoa, Alessandria, Turin, Candiolo, Ancona, Bologna

2023-09-18

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426Idiopathic Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,255

Bologna, Modena, Florence, Milan, Pisa, Roma, Ancona, Bergamo

2023-09-14

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Roma, Ancona, Bari, Cagliari, Catania, Ferrara, Florence, Milan

2023-09-13

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Ancona, Castellana Grotte, Milan, Modena, Monza, Padova, Palermo, Pisa

2023-09-07

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Ancona, Bologna, Brescia, Florence, Milan, Padua, Pisa, Roma

2023-09-05

Active, closed

Acalabrutinib Real World Italian obSErvational Study -ARISE

NCT06205498Chronic Lymphocytic Leukemia

DrugAcalabrutinib

AstraZeneca

Observational

151

Alessandria, Ancona, Bari, Barletta, Brindisi, Campobasso, Catania, Catanzaro

2023-08-08

Active, closed

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

NCT05843643Systemic Lupus Erythematosus

DrugUpadacitinib

AbbVie

Phase 3

1,014

Rome, Ancona, Padova, Pisa

2023-07-25

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Ancona, Bari, Bergamo, Catania, Milan, Monza, Naples, Palermo

2023-06-28

Recruiting

Use of Shockwave M5+/L6 IVL Catheter (Intravascular Lithotripsy) in Hostile and Calcified Iliac Access

NCT05880641Aortic Diseases, Aorto-Iliac Atherosclerosis, Peripheral Arterial Disease

EndoCore Lab s.r.l.

Observational

Ancona, Bologna, Rome, Florence, Perugia, Padova

2023-06-26

Recruiting

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100Focal Onset Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

360

Ancona, Bari

2023-05-09

Active, closed

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

288

Ancona, Cona, Padova, Pisa, Roma, Torino

2023-04-21

Active, closed

A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission

NCT05622708Non-radiographic Axial Spondyloarthritis

DrugSecukinumab

Novartis Pharmaceuticals

Phase 4

240

Ancona, Torino, Negrar, Verona

2023-03-28

Active, closed

Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

NCT05501873Atrial Fibrillation

Boston Scientific Corporation

Observational

1,173

Ancona, Mercogliano, Rivoli, Roma, Vicenza

2023-03-24

Active, closed

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan

Enliven Therapeutics

Phase 1

198

Monza, Candiolo, Aviano, Ancona, Roma, Rozzano

2023-03-20

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Ancona, Brescia, Caserta, Chieti, Catanzaro, Florence, Chiavari, Genova

2023-03-09

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Naples, Misterbianco, Bologna, Cona, Rome, Monza, Ancona, Pisa

2023-03-03

Active, closed

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

NCT05548062Polycythemia Vera

Novartis Pharmaceuticals

Observational

242

Alessandria, Ancona, Bari, Bologna, Como, Cosenza, Catania, Florence

2023-03-02

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Ancona, Chieti, Pisa, Roma

2023-02-14

Recruiting

Growth of Preterm Infants Fed a Infant Milk Formula Containing High Versus Low Amounts of Beta-palmitate

NCT04541095Weight Gain

Ospedali Riuniti Ancona

Not applicable

150

Ancona, Padua

2023-01-16

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Ancona, Naples, Meldola, Milan, Bari, Cuneo, Perugia, Rome

2023-01-16

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Rome, Ancona

2023-01-11

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

NCT05306041HER2-positive Breast Cancer

DrugsPhesgo·Inavolisib

GBG Forschungs GmbH

Phase 2

170

Alessandria, Ancona, Carpi, Lecco, Legnago, Milan, Pavia, Udine

2023-01-02

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

NCT06371170Intracardiac Thrombus

DrugRivaroxaban

Azienda Ospedaliero, Universitaria Ospedali Riuniti

Observational

Ancona

2023-01-01

Recruiting

AF Ablation With High Power Short Duration RF

NCT05777551Atrial Fibrillation, Catheter Ablation

Clinica Mediterranea

Observational

850

Mercogliano, Cotignola, Conegliano, Ancona, Asti, Naples, Torino

2023-01-01

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Ancona, Bologna, Brescia, Cagliari, Caserta, Catanzaro, Cinisello Balsamo, Florence

2022-12-27

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Ancona, Brescia, Milan, Monza, Pisa, Roma, Torino, Tricase

2022-12-23

Recruiting

European Myeloma Network (EMN) Sample Project

NCT06237803Multiple Myeloma, Smoldering Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Myeloma

European Myeloma Network B.V.

Observational

6,000

Alessandria, Ancona, Bari, Bologna, Brescia, Civitanova Marche, Florence, Genova

2022-12-21

Recruiting

COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes

NCT05633810Diabete Type 2, Cardiovascular Diseases

DrugsColchicine·Aspirin

Montreal Heart Institute

Phase 3

10,000

Foggia, Acquaviva delle Fonti, Ferrara, Ravenna, Milan, Turin, Ancona, Florence

2022-12-21

Active, closed

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

NCT05513001Chronic Spontaneous Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

696

Ancona, Milan

2022-12-09

Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

NCT05524298Low Grade Non-Hodgkin's Lymphoma, Adult

Fondazione Italiana Linfomi - ETS

Observational

150

Alessandria, Ancona, Bari, Brescia, Castelfranco Veneto, Catania, Florence, Messina

2022-12-07

Recruiting

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

NCT06894173Breast Cancer

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

1,000

Aviano, Ancona, Avellino, Brindisi, Catania, Genova, Mantua, Meldola

2022-12-03

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Ancona, Florence, Padova, Pavia, Pisa, Roma

2022-11-30

Active, closed

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

NCT05331183Cystic Fibrosis

DrugsELX/TEZ/IVA·Ivacaftor·Elexacaftor/Tezacaftor/Ivacaftor

Vertex Pharmaceuticals Incorporated

Phase 3

297

Ancona, Florence, Genova, Messina, Milan, Naples, Orbassano, Potenza

2022-11-23

Active, closed

Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia

NCT07232953Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)

DrugsTreosulfan·Fludarabine

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Phase 2

Reggio Calabria, Naples, Modena, Udine, Brescia, Milan, Cuneo, Ancona

2022-11-10

Active, closed

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257Cystic Fibrosis

DrugVNZ/TEZ/D-IVA

Vertex Pharmaceuticals Incorporated

Phase 3

822

Ancona, Florence, Genova, Milan, Orbassano, Potenza, Verona

2022-11-08

Active, closed

Xeltis Hemodialysis Access Graft: aXess Pivotal Study

NCT05473299End-stage Renal Disease

Xeltis

Not applicable

120

Ancona, Bari, Bologna, Padova, Varese

2022-11-04

Recruiting

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

NCT05924100Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia

DrugsReblozyl·Luspatercept

Associazione Qol-one

Phase 2

Alessandria, Ancona, Avellino, Biella, Catania, Chivasso, Cosenza, Florence

2022-11-03

Recruiting

National Database on Primary Sclerosing Cholangitis (PSC)

NCT05618145Primary Sclerosing Cholangitis

University of Milano Bicocca

Observational

6,000

Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte

2022-10-21

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Ancona, Bari, Bologna, Brescia, Catania, Milan, Padova, Palermo

2022-10-13

Active, closed

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

NCT05514054Breast Neoplasms

DrugsImlunestrant·Tamoxifen·Exemestane·Anastrozole

Eli Lilly and Company

Phase 3

8,000

Ancona, Bergamo, Bologna, Brindisi, Candiolo, Florence, Genova, Milan

2022-10-04

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Ancona, Catania, Foggia, Lecce, Milan, Modena, Roma, Verona

2022-09-08

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Cosenza

2022-09-08

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Modena, Rome, Milan, Catania, Siena, Ancona, Forlì, Roma

2022-09-06

Recruiting

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

NCT05386108Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms

DrugsElacestrant·Abemaciclib

Stemline Therapeutics, Inc.

Phase 1/2

Ancona, Candiolo, Meldola, Messina, Milan, Modena, Monza, Naples

2022-08-31

Active, closed

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Sjogren Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

506

Ancona, Milan, Salerno, Udine, Naples

2022-08-04

Active, closed

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046Parkinson's Disease

BlueRock Therapeutics

Observational

194

Ancona, Padova, Rome, Salerno

2022-07-29

Recruiting

The Italian Transthyretin Amyloidosis Web-Network

NCT05444920ATTR Amyloidosis

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

1,000

Legnano, Orbassano, Ancona, Bari, Bergamo, Brescia, Cagliari, Cosenza

2022-07-13

Recruiting

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248Plasmablastic Lymphoma

DrugsBortezomib·Daratumumab·Dexamethasone

Fondazione Italiana Linfomi - ETS

Phase 2

Ancona, Aviano, Florence, Miano, Monza, Naples, Roma, Palermo

2022-07-11

Active, closed

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634Myositis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2

Ancona, Milan, Pavia, Roma

2022-07-05

Active, closed

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156Endogenous Cushing's Syndrome

DrugOsilodrostat

RECORDATI GROUP

Observational

206

Ancona, Milan, Naples, Roma

2022-06-13

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

Ancona, Bari, Milan, Padova, Ravenna, Rome

2022-06-09

Active, closed

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

NCT05115110Spinal Muscular Atrophy (SMA)

DrugsRO7204239·Risdiplam

Hoffmann-La Roche

Phase 2/3

Rome, Genoa, Milan, Ancona

2022-06-02

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml

DrugELVN-001

Enliven Therapeutics

Phase 1

250

Ancona

2022-05-22

Active, closed

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

NCT05155254Metastatic Melanoma, Unresectable Melanoma

DrugsIO102-IO103·Pembrolizumab

IO Biotech

Phase 3

407

Ancona, Aviano, Bari, Candiolo, Genova, Meldola, Milan, Naples

2022-05-17

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Ancona, Bologna, Genova, Milan, Reggio Calabria, Roma, Torino, Udine

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Meldola, Rome, Milan, Catania, Siena, Ancona, Bologna, Roma

2022-03-25

Active, closed

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133Lupus Nephritis

DrugAnifrolumab

AstraZeneca

Phase 3

363

Ancona, Cona, Eboli, Padova, Roma

2022-02-15

Recruiting

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

NCT05263206Pruritus

DrugsFexofenadine·Dupilumab

Sanofi

Phase 3

284

Cona, Florence, Milan, Rozzano, Naples, Rome, Ancona

2022-02-15

Recruiting

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor, Metastatic Solid Tumor

Nuvalent Inc.

Phase 1/2

359

Ancona, Bari, Milan, Padova, Ravenna, Rome

2022-01-04

Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor

DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab

Exelixis

Phase 1

1,394

Ancona, Bologna, Florence, Milan, Naples, Ravenna

2021-12-14

Recruiting

Epidemiological Study on Invasive Bacterial Diseases

NCT06322290Invasive Bacterial Diseases (IBD)

Meyer Children's Hospital IRCCS

Observational

5,000

Adria, Ancona, Andria, Bari, Bologna, Brescia, Campobasso, Camposampiero

2021-12-09

Active, closed

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

NCT04763928Acute Myeloid Leukemia

DrugsDecitabine·Venetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

101

Alessandria, Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Castelfranco Veneto

2021-12-03

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Bologna, Ravenna, Palermo, Ancona, Florence, Padova

2021-10-27

Active, closed

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240Peripheral Artery Disease, Popliteal Aneurysm, Hemodialysis Access, Visceral Artery Aneurysms

W.L.Gore & Associates

Observational

614

Ancona, Brescia, Modena, Torino, Varese

2021-10-09

Recruiting

MYTHS - MYocarditis THerapy With Steroids

NCT05150704Myocarditis Acute

DrugMethylprednisolone

Niguarda Hospital

Phase 3

288

Ancona, Bergamo, Bologna, Brescia, Cagliari, Chieti, Florence, Genova

2021-10-07

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Milan, Rozzano, Ancona

2021-09-29

Recruiting

Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients

NCT06837766Acute on Chronic Liver Failure (ACLF)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Ancona, Bologna, Milan

2021-09-29

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Ancona, Bergamo, Milan, Modena, Monza, Padova, Palermo, Pisa

2021-09-22

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Ancona, Bari, Bologna, Meldola, Milan

2021-09-16

Active, closed

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786Advanced Breast Cancer

DrugsAlpelisib·Herceptin·Eribulin·Vinorelbine

Spanish Breast Cancer Research Group

Phase 3

Alessandria, Ancona, Bolzano, Castellanza, Catania, Cremona, Florence, Genoa

2021-09-14

Active, closed

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210Arthritis, Psoriatic

DrugsTremfya·Guselkumab

Janssen Research & Development, LLC

Phase 4

411

Ancona, Monserrato, Reggio Emilia, Roma, Rozzano (MI), Verona

2021-08-30

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Ancona, Cremona, Empoli, Florence, Milan, Perugia, Treviso

2021-08-04

Active, closed

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

NCT05312398Metastatic Colorectal Adenocarcinoma

DrugsErbitux·Folfox·Cetuximab·Irinotecan

University of Campania Luigi Vanvitelli

Phase 2

219

Ancona, Acquaviva delle Fonti, Bari, Castellana Grotte, Benevento, Brindisi, Monserrato, Catania

2021-07-15

Recruiting

CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

NCT05002543Cardiac Valve Disease

Corcym S.r.l

Observational

2,150

Ancona, Bologna, Brescia, Lecce, Massa, Milan, Naples, Palermo

2021-06-29

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Ancona, Bologna, Brindisi, Candiolo to, Catania, Genova, Meldola FC, Milan

2021-06-28

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato

2021-06-22

Active, closed

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

NCT04475731Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse

DrugPonatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Ancona, Ascoli Piceno, Avellino, Bari, Bergamo, Bologna, Brescia, Cuneo

2021-05-04

Active, closed

Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

NCT04818502Mitral Valve Regurgitation

Abbott Medical Devices

Observational

200

Ancona, Brescia, Pisa

2021-05-04

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Milan, Pozzuoli, Orbassano, Verona, Ancona, Catania, Padova

2021-04-21

Recruiting

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

NCT04442412Diffuse Large B-Cell Lymphoma, Elderly Patients

DrugCholecalciferol

Fondazione Italiana Linfomi - ETS

Phase 3

430

Brescia, Piacenza, Rionero in Vulture, Alessandria, Ancona, Ascoli Piceno, Aviano, Barletta

2021-03-23

Recruiting

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

NCT05001087Multiple Myeloma

Fondazione EMN Italy Onlus

Observational

1,900

Florence, Ancona, Bari, Bologna, Brescia, Catania, Genova, Milan

2021-03-16

Recruiting

Repaired Tetralogy of Fallot Italian Registry

NCT05288894Tetralogy of Fallot, Cardiac Death, Sudden, Cardiac Arrhythmia, Cardiac Event

Azienda Ospedaliero, Universitaria Ospedali Riuniti

Observational

150

Ancona

2021-03-01

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Meldola (fc), Ancona, Bologna, Brescia, Catania, Florence, Milan, Napoli Campania

2021-02-25

Active, closed

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

NCT04564703Multiple Myeloma

DrugIberdomide

Stichting European Myeloma Network

Phase 2

160

Ancona, Bologna, Bolzano, Brescia, Florence, Genova, Pavia, Terni

2021-02-22

Recruiting

An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias

NCT04750798Arrhythmias, Cardiac

Biosense Webster, Inc.

Observational

8,000

Acquaviva delle Fonti, Ancona, Milan, Naples

2021-02-22

Recruiting

Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution: Identification of Cardiovascular Risk in Patients with Heart Failure

NCT06884631Heart Failure

Centro Cardiologico Monzino

Observational

10,000

Milan, Ancona, Bari, Bergamo, Brescia, Foggia, Naples, Palermo

2021-02-10

Active, closed

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT04579367Hypercholesterolemia, Mixed Dyslipidemia

DrugBempedoic acid

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

5,000

Acquaviva delle Fonti, Agrigento, Ancona, Anzio, Ariccia, Ascoli Piceno, Avellino, Avezzano

2021-01-15

Active, closed

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

NCT04490915Congenital Adrenal Hyperplasia

DrugCrinecerfont

Neurocrine Biosciences

Phase 3

182

Ancona, Bologna, Florence, Messina, Milan, Naples, Padova, Roma

2020-12-16

Active, closed

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976Lung Cancer, Non-Small Cell

DrugsCobolimab·Dostarlimab·Docetaxel

GlaxoSmithKline

Phase 2/3

758

Ancona, Avellino, Florence, Milan, Monza, Naples, Orbassano to, Perugia

2020-12-08

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Catania, Milan, Ancona, Aviano, Bari, Belluno, Bologna, Brindisi

2020-12-04

Recruiting

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

NCT04184505High-risk MDS

DrugAzacitidine

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 3

274

Alessandria, Ancona, Ascoli Piceno, Bari, Bologna, Brescia, Brindisi, Castelfranco Veneto

2020-11-27

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Meldola, Rozzano, Sondrio, Trento, Ancona, Florence, Milan, Parma

2020-10-19

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Ancona, Bari, Bologna, Brescia, Cuneo, Florence, Novara, Pavia

2020-09-25

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

NCT04168502Acute Myeloid Leukemia

DrugGemtuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 3

414

Alessandria, Ancona, Ascoli Piceno, Avellino, Bari, Bologna, Caserta, Castelfranco Veneto

2020-09-24

Active, closed

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma

DrugsSelinexor·Rituximab·Dexamethasone·Gemcitabine

Karyopharm Therapeutics Inc

Phase 2/3

501

Ancona, Caserta, Naples, Novara, Pescara, Rome, Palermo, Turin

2020-09-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Bologna, Florence, Rome, Monza, Naples, Turin, Ancona, Bergamo

2020-08-31

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Ancona, Bologna, Brescia, Candiolo, Catania, Lecce, Lecco, Milan

2020-08-04

Active, closed

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

NCT04270409Plasma Cell Myeloma

DrugsMontelukast·Diphenhydramine·Acetaminophen·Isatuximab

Sanofi

Phase 3

337

Meldola, Rozzano, Ancona, Bologna, Terni

2020-06-16

Recruiting

Peripheral Extreme Revascularization in "No-option" Patiens With Chronic Limb Threatening Ischemia

NCT06277362Peripheral Arterial Disease, Critical Limb-Threatening Ischemia, Diabetic Foot

EndoCore Lab s.r.l.

Observational

Ancona, Belluno, Cesena, Conegliano, Naples, Reggio Emilia, Trento, Perugia

2020-01-31

Active, closed

Markers of Oxidative Stress in Inflammatory Bowel Diseases: Risk Factors and Implications for a Dietetic Approach

NCT04513015Inflammatory Bowel Diseases

Università Politecnica delle Marche

Not applicable

155

Ancona

2019-12-15

Active, closed

Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT

NCT04476199Acute Myeloid Leukemia

Gruppo Italiano Trapianto di Midollo Osseo

Phase 2

100

Brescia, San Giovanni Rotondo, Tricase, Monza, Ancona, Ascoli Piceno, Bari, Bologna

2019-12-09

Active, closed

Pentaglobin in CRE and PA Neutropenic Infections

NCT03494959Septic Shock

Gruppo Italiano Trapianto di Midollo Osseo

Phase 2

120

Cagliari, Naples, Ancona, Bari, Bologna, Brescia, Cuneo, Florence

2019-12-06

Recruiting

Innovative Models in the Rehabilitation of the Elderly With Parkinson's Disease Through Technological Innovation

NCT04087031Parkinson Disease, Frail Elderly, Robotic Devices in Rehabilitation

Istituto Nazionale di Ricovero e Cura per Anziani

Not applicable

195

Ancona, Fermo

2019-12-03

Active, closed

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

NCT03610438Acute Lymphoid Leukemia

DrugInotuzumab Ozogamicin

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Ancona, Ascoli Piceno, Bergamo, Bologna, Bolzano, Brescia, Cuneo, Genova

2019-10-30

Active, closed

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma

DrugsIbrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 2

175

Ponderano, Milan, Torino, Ancona, Bari, Brescia, Cagliari, Pavia

2019-09-27

Recruiting

National Database on Primary Biliary Cholangitis

NCT05151809Primary Biliary Cholangitis

University of Milano Bicocca

Observational

6,000

Ancona, Bari, Bergamo, Bologna, Bolzano, Brescia, Cagliari, Castellana Grotte

2019-09-19

Recruiting

Low INR to Minimize Bleeding With Mechanical Valves Trial

NCT03636295Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement

DrugWarfarin

Population Health Research Institute

Phase 3

2,625

Lecce, Alessandria, Ancona, Foggia

2019-09-05

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cona

2019-08-23

Active, closed

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel

Eisai Inc.

Phase 1/2

301

Ancona, Milan, Rome

2019-07-11

Active, closed

Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

NCT03731234DLBCL

DrugIbrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Castelfranco Veneto, Alessandria, Ancona, Avellino, Aviano, Bari, Brescia, Cagliari

2019-07-02

Active, closed

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

NCT04124497Multiple Myeloma, Deletion 17P Syndrome

DrugsDarzalex·Pomalidomide·Daratumumab·Dexamethasone

Fondazione EMN Italy Onlus

Phase 2

Ancona, Bari, Bergamo, Bologna, Brescia, Catania, Milan, Novara

2019-07-01

Active, closed

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

NCT04096066Multiple Myeloma, New Diagnosis Tumor

DrugsCarfilzomib·Lenalidomide·Dexamethasone

Fondazione EMN Italy Onlus

Phase 3

Alessandria, Ancona, Ascoli Piceno, Bari, Bergamo, Bolzano, Brescia, Cagliari

2019-07-01

Recruiting

Protocol ITANET - Registry

NCT04282083Gastro-entero Pancreatic Neuroendocrine Tumors

Italian Association Neuroendocrine Tumors

Observational

3,600

Rozzano, Peschiera del Garda, Ancona, Bari, Bologna, Bolzano, Brescia, Brindisi

2019-05-25

Active, closed

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

NCT03503409Myelodysplastic Syndromes, Acute Myeloid Leukemia

DrugIvosidenib

Groupe Francophone des Myelodysplasies

Phase 2

Alessandria, Ancona, Bologna, Brescia, Florence, Genova, Lecce, Milan

2019-05-14

Active, closed

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

NCT03896737Multiple Myeloma

DrugDaratumumab

European Myeloma Network B.V.

Phase 2

401

Ancona, Bergamo, Bologna, Brescia, Catania, Genova, Milan, Novara

2019-04-16

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Modena, Ancona, Catania, Rome, Verona

2019-03-25

Active, closed

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

NCT03710603Multiple Myeloma

DrugsVelcade·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

709

Ancona

2018-12-14

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Ancona, Bergamo, Bologna, Misterbianco, Milan, Rozzano, Palermo, Aviano

2018-12-07

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Ancona, Bari, Bergamo, Florence, Milan, Monza, Padova, Roma

2018-12-06

Active, closed

Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High- Risk SMM

NCT03673826Smouldering Myeloma

DrugsCarfilzomib·Lenalidomide·Dexamethasone

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 2

Ancona, Bologna, Brescia, Roma, Torino

2018-11-19

Active, closed

National Register of Actionable Mutations

NCT05918666Solid Tumours in Advanced Stages

Federation of Italian Cooperative Oncology Groups

Observational

2,098

Ancona, Arezzo, Avellino, Aviano, Bari, Bergamo, Brindisi, Catania

2018-10-27

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Bologna, Turin, Rionero in Vulture, Ancona, Milan, Palermo, Terni

2018-10-22

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Rome, Rozzano, Ancona, Catania, Milan, Naples

2018-08-09

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

NCT03435796Neoplasms

Celgene

Phase 2/3

1,541

Ancona, Bologna, Milan, Monza, Naples, Roma, Rome, Rozzano (MI)

2018-07-19

Recruiting

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

NCT03643276Acute Lymphoblastic Leukemia, Pediatric

DrugsFludarabine Phosphate·Vindesine·Tioguanin·Erwinase

Martin Schrappe

Phase 3

5,000

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Catanzaro

2018-07-15

Active, closed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851Psoriasis

DrugsEtanercept·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Ancona, Bologna, Cagliari, Padova, Reggio Emilia

2018-07-11

Active, closed

A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Folinic acid·Fluorouracil·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

565

Meldola, Monza, Vicenza, Ancona, Bergamo, Cremona, Milan, Modena

2018-06-21

Active, closed

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198Cushing Syndrome

DrugRelacorilant

Corcept Therapeutics

Phase 2

125

Ancona, Milan, Naples, Padova

2018-05-07

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Ancona, Bologna, Brescia, Cona, Genova, Lecco, Meldola, Messina

2018-03-07

Active, closed

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343EGFR-mutant Non-small Cell Lung Cancer

DrugsNazartinib·Naporafenib·Capmatinib·Gefitinib

Novartis Pharmaceuticals

Phase 1

105

Ancona, Milan, Rozzano

2018-01-29

Active, closed

A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT03319667Plasma Cell Myeloma

DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide

Sanofi

Phase 3

475

Ancona, Bergamo, Bologna, Brescia, Torino

2017-12-07

Active, closed

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

NCT03190525Multiple Myeloma

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

530

Ancona, Bologna, Brindisi, Cagliari, Catania, Catanzaro, Cona, Cosenza

2017-11-13

Recruiting

In-hospital Stellate Ganglion Block for Arrhythmic Storm

NCT05720936Arrhythmic Storm, Electrical Storm, Ventricular Fibrillation, Ventricular Tachycardia

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

500

Alessandria, Bentivoglio, Bologna, Pavia, Voghera, Legnago, Ancona, Asti

2017-11-07

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Lecce, Rome, Ancona, Bergamo, Bologna, Genova, Milan, Naples

2017-02-02

Active, closed

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661Myelodysplastic Syndromes

DrugImetelstat Sodium

Geron Corporation

Phase 2/3

289

Milan, Rozzano, Rionero in Vulture, Roma, Ancona, Bologna, Florence, Reggio Calabria

2016-01-12

Recruiting

The European NAFLD Registry

NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver

Newcastle University

Observational

10,000

Ancona, Milan, Palermo, Rome, Turin

2015-05-01

Active, closed

CINC424A2X01B Rollover Protocol

NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia

DrugsPanobinostat·Jakavi·Ruxolitinib

Novartis Pharmaceuticals

Phase 4

279

Ancona, Bari, Bologna, Brescia, San Giovanni Rotondo, Florence, Milan, Rozzano

2015-03-05

Active, closed

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599MALT Lymphoma

DrugsChlorambucil·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 2

112

Alessandria, Ancona, Aviano, Biella, Bolzano, Cagliari, Catania, Genova

2013-12

Recruiting

Italian Network MDS Registry

NCT02808858Myelodysplastic-Myeloproliferative Diseases

Fondazione Italiana Sindromi Mielodisplastiche-ETS

Observational

10,000

Alessandria, Ancona, Genova, Parma, Rionero in Vulture, Candiolo, Torino, Asti

2013-09

Active, closed

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

NCT01599559Primary Mediastinal B-cell Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Not applicable

540

Alessandria, Ancona, Aviano, Bari, Barletta, Bergamo, Bologna, Bolzano

2012-10

Active, closed

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

NCT01838512Multiple Myeloma

Bristol-Myers Squibb

Observational

2,555

Pesaro, Ancona, Cagliari, Florence, Lecce, Messina, Milan, Naples

2012-06-13

Recruiting

Product Surveillance Registry

NCT01524276Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders

Medtronic

Observational

100,000

Acquaviva delle Fonti, Ancona, Bari, Bologna, Brescia, Caserta, Castrovillari, Cotignola

2012-01

Active, closed

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

NCT02912208Myelodysplastic Syndromes, Thrombocytopenia

Associazione Qol-one

Phase 2

174

Alessandria, Ancona, Asti, Avellino, Bari, Brindisi, Cagliari, Cosenza

2011-06-11

Recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110IGF1 Deficiency

Esteve Pharmaceuticals, S.A.

Observational

500

Ancona, Bolzano, Brescia, Florence, Genova, Naples, Parma, Province of Macerata

2008-12-09

Recruiting

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Medtronic

Observational

20,000

Ancona, Bari, Bologna, Brescia, Castrovillari, Cotignola, Lecce, Milan

1983-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/ancona

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 298 of those studies with a site in Ancona.

How many clinical trials are recruiting in Ancona?

155 of the 298 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 15 have not yet opened recruitment, 125 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ancona), 298 studies
Phase	Studies	Recruiting	Share
Phase 3	121	58	40.6%
Observational	76	52	25.5%
Phase 2	49	17	16.4%
Not applicable	25	15	8.4%
Phase 1/2	9	7	3%
Phase 2/3	8	4	2.7%
Phase 1	6	2	2%
Phase 4	4	0	1.3%

Most active sponsors

Lead sponsors with the most studies (Ancona)
Lead sponsor	Studies	Recruiting
Novartis Pharmaceuticals	24	7
Fondazione Italiana Linfomi - ETS	17	9
AbbVie	13	4
AstraZeneca	12	5
Istituto Nazionale di Ricovero e Cura per Anziani	12	9
Gruppo Italiano Malattie EMatologiche dell'Adulto	7	3
Janssen Research & Development, LLC	7	2
Bristol-Myers Squibb	6	3
Boehringer Ingelheim	5	5
Eli Lilly and Company	5	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.